Particular bacteria from the gut microbiota metabolize levodopa (l-dopa), reducing bioavailability of the drug for treating Parkinson’s disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
Nature Communications Open Access 18 February 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sampson, T. R. et al. Cell 167, 1469–1480.e12 (2016).
Papavasiliou, P. S. et al. N. Engl. J. Med. 286, 8–14 (1972).
Bedarf, J. R. et al. Genome Med. 9, 39 (2017).
Hashim, H. et al. PLOS One 9, e112330 (2014).
Fasano, A. et al. Mov. Disord. 28, 1241–1249 (2013).
Zhu, H. et al. Sci. Rep. 6, 27779 (2016).
Whitfield, A. C. et al. ACS Chem. Neurosci. 5, 1192–1197 (2014).
Zimmermann, M. et al. Nature 570, 462–467 (2019).
Zimmermann, M. et al. Science 363, 6427 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Jameson, K.G., Hsiao, E.Y. A novel pathway for microbial metabolism of levodopa. Nat Med 25, 1195–1197 (2019). https://doi.org/10.1038/s41591-019-0544-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0544-x